Extensive studies with subtype A BG505-derived HIV envelope glycoprotein (Env) immunogens have revealed that the dominant autologous neutralizing epitope in rabbits is located in an exposed region of the heavily glycosylated trimer that lacks potential N-linked glycosylation sites at positions 230, 241, and 289. The Env derived from B41, a subtype B virus, shares a glycan hole centered on positions 230 and 289. To test whether broader neutralization to the common glycan hole can be achieved, we immunized rabbits with B41 SOSIP (gp120-gp41 disulfide [SOS] with an isoleucine-to-proline mutation [IP] in gp41) alone, as well as B41 and BG505 coimmunization. We isolated autologous neutralizing antibodies (nAbs) and described their structure in c...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (...
To date, immunization studies of rabbits with the BG505 SOSIP.664 HIV envelope glycoprotein trimers ...
In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used ...
In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used ...
A major advance in the search for an HIV vaccine has been the development of a near-native Envelope ...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
The native-like, soluble SOSIP.664 trimer based on the BG505 clade A env gene of HIV-1 is immunogeni...
The native-like, soluble SOSIP.664 trimer based on the BG505 clade A env gene of HIV-1 is immunogeni...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
SummaryA major advance in the search for an HIV vaccine has been the development of a near-native En...
Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) respons...
The immunogenicity of gp41-stabilized HIV-1 BG505 envelope (Env) trimers and nanoparticles (NPs) was...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (...
To date, immunization studies of rabbits with the BG505 SOSIP.664 HIV envelope glycoprotein trimers ...
In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used ...
In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used ...
A major advance in the search for an HIV vaccine has been the development of a near-native Envelope ...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
The native-like, soluble SOSIP.664 trimer based on the BG505 clade A env gene of HIV-1 is immunogeni...
The native-like, soluble SOSIP.664 trimer based on the BG505 clade A env gene of HIV-1 is immunogeni...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
SummaryA major advance in the search for an HIV vaccine has been the development of a near-native En...
Stabilized HIV-1 envelope (Env) trimers elicit tier 2 autologous neutralizing antibody (nAb) respons...
The immunogenicity of gp41-stabilized HIV-1 BG505 envelope (Env) trimers and nanoparticles (NPs) was...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Recent efforts toward HIV vaccine development include the design of immunogens that can engage B cel...
The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (...